EMI RENDON POPE: Open Payments
NPI 1417342247 · BEAUFORT, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$765 in 35 payments from 9 companies in 2025. Trend: 2023 $77 · 2024 $108 · 2025 $765
Food & beverage: $765
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $223 |
| Novo Nordisk Inc | 9 | $167 |
| Corcept Therapeutics | 4 | $100 |
| Lilly USA, LLC | 3 | $60 |
| Dexcom, Inc. | 2 | $50 |
| Amgen Inc. | 2 | $48 |
| GlaxoSmithKline, LLC. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $41 |
| Abbott Laboratories | 2 | $31 |
Products named: Korlym, BREZTRI, FARXIGA, Wegovy, Rybelsus, MOUNJARO, Dexcom G6 Transmitter, KRYSTEXXA.
Industry payments across SC — which companies pay providers there.
